Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Arvee Laboratories (India) Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
6 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
155.02
195
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
195
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Arvee Laboratories (India) Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Arvee Laboratories - Disclosure under SEBI Takeover Regulations
-
Arvee Laboratories Q4 net profit down 41.67% at Rs 0.07 cr
-
Arvee Laboratories - Outcome of Board Meeting
-
Arvee Laboratories - Outcome of Board Meeting
-
Arvee Laboratories - Board Meeting Intimation
-
Arvee Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Arvee Laboratories - Trading Window-XBRL
-
Arvee Laboratories - Trading Window
Key fundamentals
Evaluate the intrinsic value of Arvee Laboratories (India) Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 30.114 | 29.0621 | 27.0733 | 30.3174 | 20.8572 |
| Liabilities | 30.114 | 29.0621 | 27.0733 | 30.3174 | 20.8572 |
| Equity | 11.02 | 11.02 | 11.02 | 11.02 | 5.51 |
| Gross Profit | 2.9371 | 7.2815 | 5.6653 | 6.0397 | 6.0213 |
| Net Profit | 1.0518 | 4.119 | 2.5738 | 2.6773 | 2.2269 |
| Cash From Operating Activities | 3.6635 | 2.9289 | 4.0159 | 1.7105 | 10.3335 |
| NPM(%) | 3.46 | 6.71 | 6.38 | 5.65 | 4.9 |
| Revenue | 30.3451 | 61.347 | 40.3274 | 47.375 | 45.4187 |
| Expenses | 27.4079 | 54.0655 | 34.6621 | 41.3352 | 39.3973 |
| ROE(%) | 3.36 | 13.17 | 8.23 | 8.56 | 7.12 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Arvee Laboratories (India) Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Sharda Cropchem Ltd | 631.20 | 2.44 | 18.71 | 0.00 | 337.37 | 1.43 |
| Amines and Plasticizers Ltd | 220.88 | 0.54 | 29.53 | 0.00 | 361.94 | 0.23 |
| Grauer and Weil (India) Ltd | 115.60 | 0.00 | 32.66 | 0.00 | 322.62 | 0.43 |
| HP Adhesives Ltd | 51.09 | -1.37 | 25.67 | 0.00 | 99.28 | 0.00 |
Company Info
The Company was incorporated as Arvee Laboratories (India) Private Limited under the provisions of the Companies Act, 1956 vide certificate of incorporation dated January 27, 2012 in Ahmedabad, Gujarat. Subsequently, the name of the company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public company vide shareholder's approval dated September 11, 2017 and vide fresh certificate of incorporation dated September 19, 2017. KEY EVENTS AND MILESTONES IN THE HISTORY OF THE COMPANY 2012 - The Company was incorporated as Arvee Laboratories (India) Private Limited. 2013 - Acquired land, building and machineries from Skylink Chemicals Private Limited and started manufacturing unit. - Started construction of its first plant for Thiophene Derivatives. - Completes construction and commissioning of its Thiophene Derivatives Plant. 2014 - Plant inspected and approved by leading India pharmaceutical manufacturer for supply of Thiophene Derivatives. - Started construction of plant for Sulfo and Nitro Derivatives of Isophthalic Acid. - Received ISO 9001:2008 accreditation for NABCB and DAKKS from TUV NORD. - Plant inspected and approved by an American X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. - Plant inspected and approved by a European X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. 2015 - Completed construction and commissioning of plant for Nitro Derivatives of Isophthalic Acid. - After receiving inspection approval, our Company gets order for yearly supply of Nitro Derivatives of Isophthalic Acid to leading contrast media manufacturer in the United States of America. - Export to United States of America (USA) started. - Plant inspected and approved by European manufacturer for supply of Thiophene Derivatives. - Export of Thiophene Derivatives started to Europe. 2016 - Receives internal approvals for our Nitro Derivatives of Isophthalic acid from leading XRay contrast media manufacturer in Europe. - Receive approval for our Sulfo Derivatives of Isophthalic acid from a large polymer manufacturer in the United States of America and received yearly order for supply of Sulfo Derivatives to the USA. - Crossed turnover of Rs. 25 crores. 2017 - Plant inspected and approved by an American X-ray contrast media manufacturer who has the largest market share in the world and started of pilot trials with the manufacturer. - Received order for commercial trials of Nitro Derivatives of Isophthalic acid from the largest manufacturer of X-ray contrast media manufacturer in the world. - The name of our Company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public limited company. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.
The Company was incorporated as Arvee Laboratories (India) Private Limited under the provisions of the Companies Act, 1956 vide certificate of incorporation dated January 27, 2012 in Ahmedabad, Gujarat. Subsequently, the name of the company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public company vide shareholder's approval dated September 11, 2017 and vide fresh certificate of incorporation dated September 19, 2017. KEY EVENTS AND MILESTONES IN THE HISTORY OF THE COMPANY 2012 - The Company was incorporated as Arvee Laboratories (India) Private Limited. 2013 - Acquired land, building and machineries from Skylink Chemicals Private Limited and started manufacturing unit. - Started construction of its first plant for Thiophene Derivatives. - Completes construction and commissioning of its Thiophene Derivatives Plant. 2014 - Plant inspected and approved by leading India pharmaceutical manufacturer for supply of Thiophene Derivatives. - Started construction of plant for Sulfo and Nitro Derivatives of Isophthalic Acid. - Received ISO 9001:2008 accreditation for NABCB and DAKKS from TUV NORD. - Plant inspected and approved by an American X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. - Plant inspected and approved by a European X-Ray Contrast Media manufacturer and started pilot trials with the manufacturer. 2015 - Completed construction and commissioning of plant for Nitro Derivatives of Isophthalic Acid. - After receiving inspection approval, our Company gets order for yearly supply of Nitro Derivatives of Isophthalic Acid to leading contrast media manufacturer in the United States of America. - Export to United States of America (USA) started. - Plant inspected and approved by European manufacturer for supply of Thiophene Derivatives. - Export of Thiophene Derivatives started to Europe. 2016 - Receives internal approvals for our Nitro Derivatives of Isophthalic acid from leading XRay contrast media manufacturer in Europe. - Receive approval for our Sulfo Derivatives of Isophthalic acid from a large polymer manufacturer in the United States of America and received yearly order for supply of Sulfo Derivatives to the USA. - Crossed turnover of Rs. 25 crores. 2017 - Plant inspected and approved by an American X-ray contrast media manufacturer who has the largest market share in the world and started of pilot trials with the manufacturer. - Received order for commercial trials of Nitro Derivatives of Isophthalic acid from the largest manufacturer of X-ray contrast media manufacturer in the world. - The name of our Company was changed to Arvee Laboratories (India) Limited pursuant to conversion into a public limited company. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.
Read More
Parent Organisation
Arvee Laboratories (India) Ltd.
Founded
27/01/2012
Managing Director
Mr.Shalin Sudhakarbhai Patel
NSE Symbol
ARVEEEQ
FAQ
The current price of Arvee Laboratories (India) Ltd is
The 52-week high for Arvee Laboratories (India) Ltd is
The market capitalization of Arvee Laboratories (India) Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Arvee Laboratories (India) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Arvee Laboratories (India) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Arvee Laboratories (India) Ltd shares.
The CEO of Arvee Laboratories (India) Ltd is Mr.Shalin Sudhakarbhai Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
